Jefferson Shreve, Representative
sell disclosed on 22 Jun 2025 via House STOCK Act disclosures
- Transaction value
- US$15,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- Not available
Public company research profile
This public-disclosure research profile is not investment advice. It summarizes historical public filings, source links, confidence context, and hypothetical outcomes so readers can verify the evidence themselves.
Company research history
sing Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
Source-transparent disclosure history for this company, built from public CopyWindow signals and previous hypothetical outcomes.
6 disclosures
3 insiders
0 cluster signals
-2.1% avg. 30d outcome (3 of 6)
Company facts
- Ticker / ISIN
- ALNY / Not available
- Exchange
- Not available
- Country
- US
- Sector
- Not available
Disclosure history
Josh Gottheimer, Representative
buy disclosed on 15 Feb 2024 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -0.0%
Josh Gottheimer, Representative
sell disclosed on 15 Feb 2024 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -0.0%
Josh Gottheimer, Representative
sell disclosed on 7 Jan 2024 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- Not available
Daniel Goldman, Representative
buy disclosed on 17 Apr 2023 via House STOCK Act disclosures
- Transaction value
- US$15,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- -6.2%
Josh Gottheimer, Representative
buy disclosed on 16 Oct 2022 via House STOCK Act disclosures
- Transaction value
- US$1,001
- Copy Window
- Probably too late
- Data Confidence
- 93%
- Previous signal outcome
- Not available